Nivisnebart Biosimilar Monoclonal Antibody (Sortilin) for Research

Cat No.: GMP-Bios-INN-1302

Anti-SORT1/Gp95/NT3 therapeutic antibody (Pre-made Nivisnebart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Nivisnebart (development codes AL101/GSK-4527226) is a monoclonal antibody targeting sortilin 1 (SORT1). It is developed for metabolic diseases. Further development details are under investigation.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1302-1mg 1mg 3090
GMP-Bios-INN-1302-10mg 10mg
GMP-Bios-INN-1302-100mg 100mg
GMP-Bios-INN-1302-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Nivisnebart biosimilar, Whole mAb, Anti-SORT1/Gp95/NT3 Antibody: Anti-Sortilin/SORT1/100 kDa NT receptor/Glycoprotein 95 (Gp95) therapeutic antibody
INN Name Nivisnebart
Target SORT1/Gp95/NT3
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC